b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

Learn the secrets behind bold shape layers, smooth camera transitions, and the new cinematic depth of field features in After Effects Beta. #AfterEffects #MotionGraphics #VoxStyle 'He's in my car?': ...

Laurence Wall is a Contributor at DualShockers who has been writing professionally since 2022 and covering games since 2023. He primarily writes guides and lists, with a focus on indie games, RPGs, ...

Nahda Nabiilah is a writer and editor from Indonesia. She has always loved writing and playing games, so one day she decided to combine the two. Most of the time, writing gaming guides is a blast for ...

Getting a depth module in Subnautica 2 increases your tadpole submarine's depth resistance and lets you explore further without having to worry about finding oxygen spots. However, you'll reach the ...

If the UNIQUE function isn’t working in Microsoft Excel on your Windows 11/10 PC, read this post to learn how to fix the issue. The UNIQUE function extracts a list of distinct (non-duplicate) values ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

The United States applies defense-in-depth as a foundational principle in nuclear deterrence, missile defense, cyber architecture, and critical infrastructure protection. In each of these domains, the ...